Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Process for the preparation of pathogen‐inactivated RBC concentrates by using PEN110 chemistry: preclinical studies

Process for the preparation of pathogen‐inactivated RBC concentrates by using PEN110 chemistry:... BACKGROUND: A pathogen‐inactivation process for RBC concentrates is being developed by using PEN110 chemistry (INACTINE, V.I. Technologies). The objective of this study was to characterize the quality of RBCs prepared by using the PEN110 process and to measure the virucidal effect achieved against two viruses. STUDY DESIGN AND METHODS: Virology and RBC studies were conducted with standard RBC units treated with 0.1‐percent (vol/vol) PEN110 at 22°C for 6 hours. The quality of PEN110‐treated human RBCs was assessed with biochemical and phenotypic variables. The in vivo viability of PEN110‐treated RBCs in baboons was studied with the double‐label 51Cr/125I method. RESULTS: Decreases in infectious titer by inactivation of greater than a 5 log 50‐percent tissue culture infectious doses per mL of bovine viral diarrhea virus (an enveloped RNA virus) and porcine parvovirus (a nonenveloped DNA virus) was observed. RBC hemolysis was less than 1 percent after 42 days of storage, and no changes in RBC antigens were observed. The in vivo viability of PEN110‐treated baboon RBCs was unchanged from control. CONCLUSION: The preparation of RBCs by using the PEN110 process achieved a significant viral reduction of two diverse viruses without causing adverse effects to the RBCs. The process appears to be a promising approach, thus justifying further study. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Transfusion Wiley

Process for the preparation of pathogen‐inactivated RBC concentrates by using PEN110 chemistry: preclinical studies

Loading next page...
 
/lp/wiley/process-for-the-preparation-of-pathogen-inactivated-rbc-concentrates-z5HUAwrk0x

References (18)

Publisher
Wiley
Copyright
Copyright © 2002 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0041-1132
eISSN
1537-2995
DOI
10.1046/j.1537-2995.2002.00020.x
Publisher site
See Article on Publisher Site

Abstract

BACKGROUND: A pathogen‐inactivation process for RBC concentrates is being developed by using PEN110 chemistry (INACTINE, V.I. Technologies). The objective of this study was to characterize the quality of RBCs prepared by using the PEN110 process and to measure the virucidal effect achieved against two viruses. STUDY DESIGN AND METHODS: Virology and RBC studies were conducted with standard RBC units treated with 0.1‐percent (vol/vol) PEN110 at 22°C for 6 hours. The quality of PEN110‐treated human RBCs was assessed with biochemical and phenotypic variables. The in vivo viability of PEN110‐treated RBCs in baboons was studied with the double‐label 51Cr/125I method. RESULTS: Decreases in infectious titer by inactivation of greater than a 5 log 50‐percent tissue culture infectious doses per mL of bovine viral diarrhea virus (an enveloped RNA virus) and porcine parvovirus (a nonenveloped DNA virus) was observed. RBC hemolysis was less than 1 percent after 42 days of storage, and no changes in RBC antigens were observed. The in vivo viability of PEN110‐treated baboon RBCs was unchanged from control. CONCLUSION: The preparation of RBCs by using the PEN110 process achieved a significant viral reduction of two diverse viruses without causing adverse effects to the RBCs. The process appears to be a promising approach, thus justifying further study.

Journal

TransfusionWiley

Published: Feb 1, 2002

There are no references for this article.